Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | XDH | P47989 | 1/20 | 0.62 |
| ▸ | TNNI3K | Q59H18 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | PARP1 | P09874 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | TMIGD3 | P0DMS9 | 1/20 | 0.36 |
| ▸ | HTR2C | P28335 | 1/20 | 0.36 |
| ▸ | HTR2B | P41595 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15760955 | 0.80 | XDH (0.39) | XDHALDH1A1KDM4EPARP1TMIGD3 | |
| SCHEMBL15803493 | 0.79 | CYP1A2 (0.45) | XDHALDH1A1KDM4EPARP1SMN1; SMN2 | |
| SCHEMBL1996891 | 0.77 | XDH (1.00) | XDHTNNI3KKDM4ESMN1; SMN2TMIGD3 | |
| SCHEMBL15760952 | 0.74 | PARP1 (0.43) | XDHALDH1A1PARP1 | |
| SCHEMBL15760950 | 0.74 | PDPK1 (0.40) | XDHALDH1A1PARP1 | |
| SCHEMBL15760947 | 0.69 | PARP1 (0.38) | XDHPARP1TMIGD3 | |
| SCHEMBL130696 | 0.68 | XDH (0.57) | XDH | |
| SCHEMBL18742201 | 0.68 | PARP1 (0.42) | ALDH1A1PARP1 | |
| SCHEMBL11295050 | 0.67 | PARP1 (0.49) | ALDH1A1KDM4EPARP1 | |
| SCHEMBL15760953 | 0.67 | PDPK1 (0.39) | XDHALDH1A1KDM4EPARP1TMIGD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140171429-A1 | BICYCLIC INHIBITORS OF ALK | ABBVIE INC. (US) | 2014-06-19 | — | — | US | disclosed |
| US-20140155389-A1 | BICYCLIC INHIBITORS OF ALK | ABBVIE INC. (US) | 2014-06-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140171429-A1 | BICYCLIC INHIBITORS OF ALK | ALK, ACVR1, ACVR1B | XDH 1213/4885TNNI3K 276/4885ALDH1A1 161/4885 |
| US-20140155389-A1 | BICYCLIC INHIBITORS OF ALK | ALK, ABL1, BOD1L1 | XDH 603/4885TNNI3K 251/4885ALDH1A1 140/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.